Investigating the methods of production of Human Insulin by Genetic engineering

Dwij Doshi
Dwij Doshi, Rahul International School, Mira Road, Thane, Maharashtra 401107
doi.org/10.64643/IJIRTV12I4-184438-459

Abstract- The production of human insulin through genetic engineering represents one of the most significant achievements in biotechnology, revolutionizing diabetes treatment worldwide. This investigation reveals that two primary methods are employed for recombinant human insulin production: the two-chain method and the proinsulin method, both utilizing genetically modified *Escherichia coli* bacteria as expression systems. The development of these techniques has eliminated dependence on animal-derived insulin, providing diabetic patients with unlimited supplies of pure human insulin while avoiding immunological complications associated with foreign proteins. Modern production processes achieve yields of over 2 grams of insulin per liter of bacterial culture, making therapeutic insulin both accessible and cost-effective for millions of patients globally.

Index Terms – Recombinant insulin, Genetic engineering, Proinsulin method, *Escherichia coli,* Plasmid vector production

I. INTRODUCTION

Insulin, a vital peptide hormone consisting of 51 amino acids arranged in two polypeptide chains (A chain: 21 amino acids, B chain: 30 amino acids), plays a crucial role in glucose homeostasis within the human body. Prior to the advent of genetic engineering, insulin for diabetic patients was exclusively extracted from the pancreases of slaughtered pigs and cattle, a process that presented significant limitations including supply constraints, potential allergic reactions, and the risk of pathogen transmission. The breakthrough development of recombinant DNA technology in the 1970s opened new possibilities for producing unlimited quantities of pure human insulin through genetically modified microorganisms.

The first successful production of human insulin using genetic engineering was achieved by Genentech in 1978, marking the beginning of a new era in pharmaceutical biotechnology. This pioneering work led to the approval of Humulin by the FDA in 1982, becoming the first recombinant DNA-derived therapeutic protein approved for human use. The success of genetically engineered insulin production not only transformed diabetes treatment but also established the foundation for the modern biotechnology industry, demonstrating the practical applications of molecular biology techniques in medicine



13.12: David McIntyre.

II.THEORY

Background and Historical Development

The journey toward genetically engineered insulin began with Frederick Sanger's determination of insulin's primary structure in 1955, which revealed the exact sequence of amino acids in both the A and B chains. This fundamental knowledge provided the blueprint necessary for synthetic production methods. The development of restriction enzymes and DNA ligases in the early 1970s created the molecular tools required for precise DNA manipulation, enabling scientists to cut and paste genetic material with unprecedented accuracy.

The initial breakthrough came from the realization that bacterial cells, despite being prokaryotic organisms, possess the same genetic code as eukaryotic cells, allowing them to read and express human genes when properly introduced. The choice of Escherichia coli as the primary expression system was strategic, as these bacteria are well-characterized, easy to manipulate genetically, grow rapidly on inexpensive media, and can be cultured in large-scale fermentation systems.



Structure and Function of Human Insulin

Human insulin exhibits a complex three-dimensional structure stabilized by three disulfide bonds: two interchain bonds connecting the A and B chains (A7-B7 and A20-B19) and one intrachain bond within the A chain (A6-A11). These disulfide bonds are essential for insulin's biological activity, as demonstrated by studies showing that removal of any single disulfide bond results in complete loss of receptor binding capability. The spatial arrangement created by these bonds allows insulin to adopt its active conformation(tertiary protein structure) necessary for binding to insulin receptors on target cells.

The hormone is naturally synthesized in pancreatic β-cells as preproinsulin, which contains a signal peptide for cellular transport, followed by the B chain, C-peptide (connecting peptide), and A chain in a single polypeptide sequence. During normal biosynthesis, the signal peptide is removed to form proinsulin, which is subsequently processed by specific endoproteases to yield mature insulin and C-peptide. This natural processing pathway provided important insights for developing artificial production methods.



Two-Chain Method of Insulin Production

The two-chain method, pioneered by Genentech in 1978, involves the separate production of insulin A and B chains in different bacterial cultures, followed by their chemical combination to form active insulin. This approach requires the synthesis of two distinct complementary DNA (cDNA) sequences encoding the A chain (21 amino acids) and B chain (30 amino acids) respectively, based on the known protein sequence and optimized for E. coli codon usage.

The process begins with the chemical synthesis of the insulin genes rather than isolation from natural sources, since the exact DNA sequence was unknown at the time of development. Each synthesized gene is inserted into separate plasmid vectors using restriction endonucleases, typically next to the *lacZ* gene encoding β-galactosidase to create fusion proteins. The resulting recombinant plasmids are introduced into *E. coli* cells through transformation, where the bacteria produce fusion proteins containing β-galactosidase linked to either insulin A or B chain peptides.

After bacterial fermentation, the fusion proteins are extracted and purified, followed by chemical cleavage to separate the insulin chains from β-galactosidase. The purified A and B chains are then combined under controlled oxidative conditions to promote disulfide bond formation, yielding mature, biologically active human insulin. This refolding process requires precise control of pH, temperature, and oxidizing agents to ensure proper disulfide bond formation and prevent aggregation

Proinsulin Method of Insulin Production

The proinsulin method, developed in the mid-1980s, represents a more efficient approach involving the production of a single-chain insulin precursor that more closely mimics the natural biosynthetic pathway. This method utilizes a chemically synthesized gene encoding human proinsulin, which contains the B chain, C-peptide, and A chain in the correct sequence for proper folding.

The proinsulin gene is inserted into E. coli expression vectors, often fused with bacterial signal sequences to facilitate protein secretion into the periplasmic space. This approach offers several advantages over the two-chain method: single fermentation reduces production complexity, natural folding occurs spontaneously due to the connecting C-peptide, and higher yields are typically achieved.

Following bacterial expression and purification of proinsulin, the molecule undergoes enzymatic processing using trypsin and carboxypeptidase B to remove the C-peptide, yielding mature insulin. This enzymatic cleavage mimics the natural processing that occurs in pancreatic β-cells, ensuring production of insulin with native structure and full biological activity. The proinsulin method has become the preferred commercial production route due to its efficiency and scalability.



Genetic Engineering Techniques

Gene Isolation and Synthesis

The production of recombinant insulin requires precise genetic construction techniques starting with the design of synthetic genes optimized for bacterial expression. Since the natural human insulin gene contains introns and regulatory sequences incompatible with bacterial systems, completely synthetic genes are designed based on the known protein sequence. These synthetic genes incorporate codon optimization to match the codon usage preferences of E. coli, enhancing translation efficiency and protein yield.

Restriction Enzyme Cloning

Restriction endonucleases serve as molecular scissors for precise DNA manipulation, recognizing specific palindromic sequences and creating compatible sticky ends for DNA joining. For insulin gene cloning, commonly used enzymes include EcoRI, BamHI, and HindIII, which create predictable cut patterns allowing directional insertion of genes into vectors. The same restriction enzyme must be used to cut both the insulin gene and the plasmid vector to ensure compatible sticky ends that can be joined by DNA ligase.

Vector Construction and Transformation

Plasmid vectors used for insulin production typically contain multiple essential elements: antibiotic resistance genes for selection of transformed bacteria, origin of replication for plasmid maintenance, promoter sequences for gene expression control, and restriction sites for gene insertion. The most commonly used vectors are derivatives of pBR322 and pUC plasmids, which provide stable replication and high copy numbers in E. coli.

Transformation of bacterial cells with recombinant plasmids is achieved through various methods including calcium chloride treatment, electroporation, or heat shock procedures. Selection of successfully transformed bacteria relies on antibiotic resistance markers, with only cells containing the recombinant plasmid surviving on selective media

Fermentation and Large-Scale Production

Bioreactor Design and Operation

Industrial insulin production utilizes sophisticated bioreactor systems designed to maintain optimal conditions for bacterial growth and protein expression. These systems typically employ fed-batch fermentation processes where nutrients are continuously added to sustain high cell densities while controlling metabolic byproduct accumulation. Critical parameters include temperature (37°C), pH (7.0), dissolved oxygen levels (30% saturation), and nutrient feed rates.

Modern production facilities can achieve bacterial cell densities exceeding 300 grams per liter (wet cell weight) with insulin expression levels of 2-3 grams per liter of culture medium. The fermentation process typically runs for 5-7 days, with careful monitoring of cell growth, protein expression, and product quality throughout the production cycle.

Expression Systems and Host Strain Development

While E. coli remains the predominant expression system for insulin production, alternative hosts including Saccharomyces cerevisiae (baker's yeast) and Pichia pastoris have been developed for specific applications. Yeast systems offer advantages in terms of post-translational modifications and protein secretion, though bacterial systems generally provide higher yields and lower production costs.

Advanced E. coli strains have been engineered with enhanced characteristics including reduced protease activity, improved protein folding capabilities, and increased resistance to cellular stress conditions. These improvements have resulted in significant increases in insulin yield and quality while reducing production time and costs.

Purification and Processing Methods

Inclusion Body Recovery and Solubilization

In bacterial expression systems, recombinant insulin proteins often accumulate as inclusion bodies - insoluble aggregates within the bacterial cytoplasm. While initially considered problematic, inclusion bodies actually provide several advantages: protection from proteolytic degradation, simplified purification procedures, and high protein purity. Recovery involves bacterial cell lysis followed by centrifugation to isolate inclusion bodies from soluble cellular components.

Inclusion body solubilization requires treatment with denaturing agents such as urea or guanidine hydrochloride under reducing conditions to break disulfide bonds. The solubilized protein must then undergo refolding procedures to restore native structure and biological activity. This process requires careful control of conditions including pH, temperature, protein concentration, and the presence of folding aids.

Chromatographic Purification

The purification of recombinant insulin employs multiple chromatographic techniques to achieve pharmaceutical-grade purity. Ion exchange chromatography separates proteins based on charge differences, effectively removing bacterial proteins and insulin variants. Size exclusion chromatography provides separation based on molecular size, eliminating aggregated proteins and low molecular weight impurities.

Reversed-phase high-performance liquid chromatography (RP-HPLC) serves as the final purification step, capable of resolving closely related insulin species and achieving purities exceeding 99%. This technique has been successfully scaled for production of kilogram quantities of pharmaceutical-grade insulin. The purified insulin undergoes crystallization to produce the final pharmaceutical product, with zinc chloride typically added to promote hexamer formation and stability.

Quality Control and Characterization

Structural Verification

Recombinant human insulin must meet stringent quality standards to ensure safety and efficacy. Mass spectrometry provides precise molecular weight determination and detection of structural variants or degradation products. Amino acid sequencing confirms the correct primary structure, while peptide mapping after enzymatic digestion verifies proper disulfide bond formation.

Circular dichroism spectroscopy and nuclear magnetic resonance techniques assess secondary and tertiary structure, ensuring the recombinant protein adopts the same conformation as native human insulin. X-ray crystallography of purified insulin crystals provides definitive structural confirmation.

Biological Activity Testing

The biological activity of recombinant insulin is assessed through multiple assays including receptor binding studies, glucose oxidation assays in isolated adipocytes, and blood glucose lowering in animal models. These tests confirm that the genetically produced insulin retains full biological potency equivalent to native human insulin. Immunogenicity testing ensures the recombinant product does not elicit unwanted immune responses.

Advantages and Applications of Genetically Engineered Insulin

Clinical Benefits

Genetically engineered human insulin offers numerous advantages over animal-derived insulin. The identical amino acid sequence to native human insulin eliminates immunogenic reactions that occurred with porcine and bovine insulin, which differ by 1-3 amino acids respectively. This improvement has significantly reduced the incidence of insulin allergies and lipodystrophy at injection sites.

The unlimited supply provided by bacterial production systems has eliminated concerns about insulin shortages that previously constrained diabetes treatment. Production costs are substantially lower than animal extraction methods, making insulin therapy more accessible globally. Consistent quality and purity are achieved through standardized production processes, eliminating batch-to-batch variations inherent in animal-derived products.

Development of Insulin Analogs

The genetic engineering platform has enabled development of modified insulin analogs with altered pharmacokinetic properties tailored for specific therapeutic needs. Rapid-acting analogs such as insulin lispro and aspart provide faster onset and shorter duration of action, improving postprandial glucose control. Long-acting analogs including insulin glargine and detemir offer extended duration with reduced peak effects, providing improved basal insulin replacement.

These analogs are produced using the same recombinant DNA techniques with modified gene sequences encoding amino acid substitutions that alter protein stability, aggregation behavior, or receptor binding kinetics. The ability to precisely engineer insulin properties represents a major advancement in personalized diabetes therapy.

Industrial and Economic Impact

The success of genetically engineered insulin established the biotechnology industry as a major pharmaceutical sector. The technology has been licensed globally, with major production facilities operating in multiple countries to meet worldwide insulin demand. Economies of scale in bacterial production have made insulin therapy affordable even in developing nations.

The expertise developed through insulin production has been applied to numerous other therapeutic proteins including growth hormone, interferons, and clotting factors. This technology transfer has accelerated development of the broader biopharmaceutical industry.



III. CONCLUSION

The investigation into methods of human insulin production by genetic engineering reveals a remarkable transformation in pharmaceutical manufacturing that has revolutionized diabetes treatment worldwide. The development of two primary production methods - the two-chain approach and the more efficient proinsulin method - demonstrates the evolution of biotechnology from experimental concept to industrial reality. Both methods successfully utilize *Escherichia coli* bacteria as expression systems, achieving production yields exceeding 2 grams of insulin per liter while maintaining pharmaceutical-grade purity and full biological activity.

The genetic engineering techniques employed in insulin production showcase fundamental molecular biology principles including restriction enzyme cloning, plasmid vector construction, bacterial transformation, and protein expression systems. These methods have eliminated dependence on animal-derived insulin, providing unlimited supplies of human insulin while avoiding immunological complications and ensuring consistent quality.

Advanced purification technologies including chromatographic separation and inclusion body processing have achieved remarkable success in producing insulin that meets stringent pharmaceutical standards. The integration of fermentation science with molecular biology has created scalable production systems capable of meeting global insulin demand while continuously reducing costs.

The success of genetically engineered insulin extends beyond diabetes treatment, establishing the foundation for the modern biotechnology industry and enabling development of numerous other therapeutic proteins. The technology has facilitated creation of modified insulin analogs with tailored pharmacokinetic properties, providing personalized therapeutic options for diabetic patients. This achievement represents one of the most significant applications of genetic engineering in medicine, demonstrating the profound impact of biotechnology on human health and establishing a model for future pharmaceutical innovations.

Looking forward, ongoing research focuses on developing more efficient expression systems, improving production yields, and creating novel insulin formulations with enhanced therapeutic properties. The principles established through insulin production continue to guide development of next-generation biopharmaceuticals, ensuring that this pioneering achievement will remain relevant for future advances in genetic engineering and therapeutic protein production.

REFERENCE

[1] BBC Bitesize. (Nov. 2019). Genetic engineering (CCEA) Insulin production. BBC Bitesize. [Online]. Available: https://www.bbc.co.uk/bitesize/guides/zr3f7nb/revision/2
[2] Vedantu. (Jul. 2024). Write the steps in the production of human insulin by genetic engineering. Vedantu Question Answer. [Online]. Available: https://www.vedantu.com/question-answer/write-the-steps-in-the-production-of-human-class-12-biology-cbse-5f6420332ac31d63478933b5
[3] A.D. Riggs. (Dec. 2020). Making, Cloning, and the Expression of Human Insulin Genes in Bacteria: The Path to Humulin. Diabetes Technol Ther. [Online]. 23(S1). pp. S-4-S-18. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC8152450/
[4] Study.com. (May 2019). Insulin | Overview & Production - Lesson. Study.com Academy. [Online]. Available: https://study.com/ academy/lesson/genetic-engineering-insulin-production.html
[5] M. Sadeghian et al. (Apr. 2015). Equivalent Recombinant Human Insulin Preparations and their Place in Therapy. Eur Endocrinol. [Online]. 11(1). pp. 10-16. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC5819055/
[6] Chemistry LibreTexts. (Mar. 2025). 8.8: Genetic engineering. Chemistry LibreTexts. [Online]. Available: https://chem.libretexts.org/Bookshelves/Introductory_Chemistry/Introduction_to_Organic_and_Biochemistry_(Malik)/08:_Nucleic_acids/8.08:_Genetic_engineering
[7] M.N. Baeshen et al. (Sep. 2021). Human Insulin: History, Recent Advances, and Expression Systems for Production. Biomed Res Int. [Online]. 2014:462594. Available: https://bmrat.org/index.php/BMRAT/article/view/692
[8] Gyan Sanchay. (Feb. 2022). Insulin Production - Expression of Insulin gene & production in E. coli. Gyan Sanchay Repository. [Online]. Available: https://gyansanchay.csjmu.ac.in/wp-content/uploads/2022/02/Insulin-Production.pdf
[9] M. Zieliński et al. (2019). Expression and purification of recombinant human insulin from E. coli strain. Protein Expr Purif. [Online]. 157. pp. 63-69. Available: https://www.sciencedirect.com/science/article/pii/S1046592818305862
[10] SlideShare. (Nov. 2019). Insulin production by genetic engineering. SlideShare Presentation. [Online]. Available: https://www.slideshare.net/slideshow/insulin-production-by-genetic-engineering-189661918/189661918
[11] Oxford Biology. (Sep. 2021). Animation E4, 1.1 Production of human insulin. YouTube Educational Video. [Online]. Available: https://www.youtube.com/watch?v=y4AMgE6B5jI
[12] Doubtnut. (Sep. 2019). Explain the steps involved in the production of genetically engineered insulin. Doubtnut Educational Platform. [Online]. Available:https://www.doubtnut.com/qna/37611724
[13] BYJU'S. (Sep. 2023). The Need for Preparing Genetically Engineered Insulin. BYJU'S NEET Preparation. [Online]. Available: https://byjus.com/neet/genetically-engineered-insulin/
[14] Vedantu. (Aug. 2025). Genetically Engineered Insulin - Production, Types, Structure. Vedantu NEET Guide. [Online]. Available: https://www.vedantu.com/neet/genetically-engineered-insulin
[15] Allen Career Institute. (May 2025). Genetically Engineered Insulin: Definition, Production & Types. Allen NEET Biology. [Online]. Available: https://allen.in/neet/biology/genetically-engineered-insulin
[16] D.J. Groskreutz, M.X. Sliwkowski, C.M. Gorman. (Feb. 1994). Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J Biol Chem. [Online]. 269(8). pp. 6241-6245. Available: https://pubmed.ncbi. nlm.nih.gov/8119968/
[17] EdTech Books. (n.d.). 12 - Gene Cloning. Genetics and Molecular Biology Textbook. [Online]. Available: https://books.byui.edu/genetics_and_molecul/23___gene_cloning
[18] H. Nasri et al. (Jun. 2012). Construction of Plasmid Insulin Gene Vector Containing

Glucose-Inducible Promoter. Iran J Basic Med Sci. [Online]. 16(3). pp. 269-276. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC3693627/

[19] F. Barbetti et al. (Jan. 1996). Synthesis and processing of genetically modified human proinsulin. Diabetologia. [Online]. 39(2). pp. 199-205. Available: https://pubmed.ncbi.nlm. nih.gov/8825870/

[20] SnapGene. (Dec. 2021). Restriction Enzyme Cloning - Guide. SnapGene Resources. [Online]. Available:https://www.snapgene.com/guides/restriction-enzyme-cloning

[21] World Intellectual Property Organization. (Apr. 1997). Plasmid for producing human insulin. Patent WO1983000164A1. [Online]. Available: https://patents.google.com/patent/WO1983000164A1/en

[22] J.W. Campbell et al. (Jun. 2020). Revisiting Proinsulin Processing: Evidence That Human β-Cells Process Proinsulin With Prohormone Convertase 1/3 but Not Prohormone Convertase 2. Diabetes. [Online]. 69(7). pp. 1451-1462. Available:https://diabetesjournals.org/diabetes/article/69/7/1451/39562/Revisiting-Proinsulin-Processing-Evidence-That

[23] Save My Exams. (Jul. 2025). Manufacturing Human Insulin. Edexcel IGCSE Biology Revision. [Online]. Available: https://www.savemyexams.com/igcse/biology/edexcel/19/revision-notes/5-use-of-biological-resources/genetic-modification-genetic-engineering/manufacturing-human-insulin/

[24] P.S. Monzani et al. (Jan. 2024). Human proinsulin production in the milk of transgenic cattle. Biotechnol J. [Online]. 19(1). e2300307. Available:https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/biot.202300307

[25] R.A. Abdulkareem. (2019). Cloning and Expression of Recombinant Human Insulin Gene in Pichia pastoris. Int J Pharm Qual Assur. [Online]. 10(1). pp. 136-141. Available: https://impactfactor.org/PDF/IJPQA/10/IJPQA,Vol10,Issue1,Article22.pdf

[26] N. Farrokhi et al. (Feb. 2014). Cloning, Transformation and Expression of Proinsulin Gene in Tomato Plants. J Sci Food Agric. [Online]. 94(12). pp. 2484-2490. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC3957137/

[27] SlideShare. (Jun. 2018). Cloning of the insulin genes. SlideShare Educational Presentation. [Online]. Available: https://www.slideshare.net/slideshow/cloning-of-the-insulin-genes/101412967

[28] E.P. Kroeff et al. (1989). Production scale purification of biosynthetic human insulin by reversed-phase high-performance liquid chromatography. J Chromatogr. [Online]. 461. pp. 45-61. Available: https://pubmed.ncbi. nlm. nih.gov/2651467/

[29] S.G. Chang et al. (Dec. 2003). Role of disulfide bonds in the structure and activity of human insulin. Mol Cells. [Online]. 16(3). pp. 323-330. Available:https://pubmed.ncbi.nlm.nih.gov/14744022/

[30] E.P. Kroeff et al. (1989). Production scale purification of biosynthetic human insulin by reversed-phase high-performance liquid chromatography. J Chromatogr. [Online]. 461. pp. 45-61. Available: https://www.sciencedirect.com/science/article/pii/S0021967300942742

[31] M. Nishiyama et al. (Dec. 2012). Insulin analog with additional disulfide bond has increased stability and maintained activity. Protein Sci. [Online]. 22(3). pp. 406-413. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC3595460/

[32] SlideShare. (Sep. 2017). Industrial production of insulin. SlideShare Technical Presentation. [Online]. Available: https://www.slideshare.net/slideshow/industrial-production-of-insulin/80106483

[33] P. Cuatrecasas. (May 1972). Affinity Chromatography and Purification of the Insulin Receptor of Liver Cell Membranes. Proc Natl Acad Sci USA. [Online]. 69(5). pp. 1277-1281. Available:https://pmc.ncbi.nlm.nih.gov/articles/PMC426681/

[34] X. Li et al. (May 2014). An Iodine-Free and Directed-Disulfide-Bond-Forming Route to Insulin. Org Lett. [Online]. 16(11). pp. 3090-3093. Available:https://pubs.acs.org/doi/10.1021/ol501252b

[35] Y. Kang et al. (Nov. 2016). A Simplified and Efficient Process for Insulin Production in Pichia pastoris. PLoS One. [Online]. 11(11). e0167732.

Available:https://pmc.ncbi.nlm.nih.gov/articles/PMC5131935/
[36] Hanbon Sci & Tech. (Jul. 2025). Insulin & Peptide Purification Methods. Hanbon Technical Resources. [Online]. Available: https://www.jshanbon.com/insulin-and-peptide-purification/
[37] Z.L. Wan et al. (Dec. 2017). Insulin in motion: The A6-A11 disulfide bond allosterically modulates structural transitions required for insulin activity. Sci Rep. [Online]. 7(1). Article 17239. Available: https://www.nature. Com /articles/s41598-017-16876-3